The race to treat a number of health conditions using neurostimulation technology is a marathon, not a sprint—but Medtronic and Axonics Modulation Technologies are still aiming for a photo finish. For ...

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation ...

Competition in the sacral neuromodulation space continues to breed new options for patients with bladder and bowel dysfunction. Irvine, CA-based Axonics now has FDA approval for its recharge-free ...

Medtronic is upping the ante in patent dispute with competitor Axonics Inc. that has already lasted more than four years. The dispute centers on Medtronic's InterStim device, an implanted ...

Medtronic and Axonics have been going toe-to-toe in sacral neuromodulation — a fast-growing market that was monopolized by Medtronic until September 2019 — and the incumbent may have just gained the ...

Barely a month after winning FDA clearance for its long-lasting implant to treat bladder dysfunction, Axonics is wasting no time in bringing the device to the masses. The Southern California-based ...

Axonics Modulation Technologies Inc. Chief Executive Ray Cohen is nothing if not confident about becoming the market leader in his urology device category, despite renewed competition from medtech ...

Sept 19 (Reuters) - Medical device maker Axonics has convinced a jury in California federal court that it did not violate rival Medtronic's (MDT.N), opens new tab patent rights in nerve-stimulation ...

DUBLIN, Sept. 22, 2021 /PRNewswire/ -- Medtronic (NYSE:MDT), the global leader in medical technology, today announced that the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark ...

AXNX reported impressive 1Q23 earnings with revenue of $70.7 million, representing a remarkable 46% year-on-year growth. The success of Axonics' F15 and Bulkamid products played a significant role in ...